author-photo

Sharoon Akhtar

Mayo Clinic

40

Papers

331

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL)

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (15)
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

2018 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (8)
Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity

2018 ChemMedChem
Show All
- Source
- Cite
- Save
Citations (6)
Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

2017 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (31)
The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

2016 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (34)
VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)